16 September 2009

NICE

Latest Implementation Tools (9th September 2009)
Tools to aid implementation of latest NICE guidance.

Schizophrenia (update): Guide to Resources

TA176 Colorectal cancer (first line) - cetuximab: Costing Template and Audit Support

TA177 Eczema (chronic) - alitretinoin: Costing Template and Audit Support

TA178 Renal Cell Carcinoma: Costing Statement and Audit Support

IPG311 Extracorporeal shockwave therapy for refractory plantar fasciitis: Audit Support

IPG313 Extracorporeal shockwave therapy for refractory tennis elbow: Audit Support

IPG314 Ultrasound-guided foam sclerotherapy for varicose veins: Audit support


School-based interventions to prevent smoking: consultation on the draft guidance (3rd September 2009)
NICE is developing public health intervention guidance School-based interventions to prevent the uptake of smoking among children.

All registered stakeholders for the above public health intervention guidance are invited to comment on the draft guidance.

Closing date for comments is 1st October 2009.
Consultation


Hypertensive disorders during pregnancy: draft guideline consultation (3rd September 2009)
A clinical practice guideline on Hypertensive disorders during pregnancy is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations via this website.

Closing date for comments is 29th October 2009.
Consultation


Donor breast milk banks: guideline consultation (8th September 2009)
A clinical practice guideline on Donor breast milk banks is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations via this website.

Closing date for comments is 6th October 2009.
Consultation


Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line): appraisal consultation 2 (9th September 2009)
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE) to produce guidance on using sorafenib for the treatment of advanced hepatocellular carcinoma in the NHS in England and Wales. The Appraisal Committee has had its third meeting to consider the evidence submitted by the manufacturer and the views of non-manufacturer consultees and commentators, and clinical specialists and patient experts.

Closing date for comments is 30th September 2009.
Consultation


Cervical cancer (recurrent) - topotecan: final appraisal determination (10th September 2009)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Cervical cancer (recurrent) – topotecan and submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note that the appeal period for this appraisal will close at 5pm on 25 September 2009.
FAD


Preventing and reducing HIV transmission among African communities: consultation on the draft scope (11th September 2009)
NICE is developing public health intervention guidance on preventing and reducing HIV transmission among African communities living in England: guidance for sexual health services

All registered stakeholders for the above public health intervention guidance are invited to comment on the draft scope.

Closing date for comments is 9th October 2009.
Consultation


Preventing and reducing HIV transmission among men who have sex with men: draft scope consultation (11th September 2009)
NICE is developing public health intervention guidance on preventing and reducing HIV transmission among African communities living in England: guidance for sexual health services

All registered stakeholders for the above public health intervention guidance are invited to comment on the draft scope.

Closing date for comments is 9th October 2009.
Consultation


Crohn's disease - infliximab (review) and adalimumab: appraisal consultation (14th September 2009)
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of infliximab and adalimumab for the treatment of Crohn's disease and provide guidance on their use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of infliximab and adalimumab.

Closing date for comments is 7th October 2009.
Consultation

No comments: